Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
C4X Discovery
C4X Discovery
Activities:
Research & Development
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates
The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Drug Delivery
C4XD signs $402 million licence with AstraZeneca
C4XD is eligible to receive upfront and pre-clinical payments of $16 million, plus development and commercial milestones, and tiered mid-single digit royalties
Research & Development
C4XD receives first milestone payment of €3 million from Sanofi
€3 million milestone payment triggered by preclinical progression in oral IL-17A inhibitor programme
Research & Development
C4X Discovery buys genetic platform provider Adorial for £1.7m
Adorial's mathematical tool Taxonomy3 has the potential to increase small molecule drug development success
Research & Development
C4X Discovery appoints Piers Morgan as Chief Executive
Succeeds Sam Williams who returns to Non-Executive Director role
Research & Development
UK biotechs win Biomedical Catalyst funding of almost £100m
Thirty-three UK companies have received business-led awards
Subscribe now